Loading…

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Saved in:

Bibliographic Details
Published in:	Transplantation and cellular therapy 2022-03, Vol.28 (3), p.S56-S57
Main Authors:	Kamdar, Manali, Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco J, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G., Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, Abramson, Jeremy S.
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!